Enormous progress has been made in the last half-century in the management of diseases
closely integrated with excess body weight, such as hypertension, adult-onset diabetes and …

Patients with type 2 diabetes are at high risk for development of cardiovascular disease,
including myocardial infarction, stroke, heart failure, and cardiovascular death. Multiple large …

Background Semaglutide, a glucagon-like peptide-1 receptor agonist, has been shown to
reduce the risk of adverse cardiovascular events in patients with diabetes. Whether …

Background Retatrutide (LY3437943) is an agonist of the glucose-dependent insulinotropic
polypeptide, glucagon-like peptide 1, and glucagon receptors. Its dose–response …

Importance Phase 3 trials have not compared semaglutide and liraglutide, glucagon-like
peptide-1 analogues available for weight management. Objective To compare the efficacy …

Background This trial assessed the efficacy and safety of the GLP-1 analogue once a week
subcutaneous semaglutide 2· 4 mg versus semaglutide 1· 0 mg (the dose approved for …

Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP1)
exhibit incretin activity, meaning that they potentiate glucose-dependent insulin secretion …

Background Glucagon-like peptide-1 receptor agonists (GLP1RA) augment glucose-
dependent insulin release and reduce glucagon secretion and gastric emptying, enabling …

The ongoing obesity epidemic represents a global public health crisis that contributes to
poor health outcomes, reduced quality of life, and> 2.8 million deaths each year. Obesity is …

Background Chronic kidney disease (CKD) is a common complication of type 2 diabetes
(T2D). Glucagon-like peptide-1 receptor agonists (GLP-1RAs) improve glycaemic control …